Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:11:54.814Z.
Calculation as of: 2026-10-06T17:11:54.814Z.
Quote observation: 2026-10-06T17:08:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a9a1b17caad0ab37430e79e816a911291535ac0fb348029df9f580b63ef335
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Cadrenal Therapeutics, Inc. Common Stock
Market Cap
$3.35M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.25M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.16M
PS Ratio
N/A
TTM Avg
71.18
3Y Avg
73.71
5Y Avg
73.71
Market Cap
$3.49M
PS Ratio
N/A
TTM Avg
141717.15
3Y Avg
141717.15
5Y Avg
141717.15
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $3.35M | N/A | N/A | N/A | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.29M | N/A | 69.25 | 700.44 | 2108.35 |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.25M | N/A | N/A | N/A | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.21M | N/A | N/A | N/A | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.16M | N/A | 71.18 | 73.71 | 73.71 |
| IceCure Medical Ltd (ICCM)vs › | $3.15M | 0.80 | 8.88 | 13.52 | 16.08 |
| Revelation Biosciences, Inc. (REVB)vs › | $3.12M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | 141717.15 | 141717.15 | 141717.15 |
| Eocene Ltd. (EOCN)vs › | $3.54M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.55M | 16.35 | 54.87 | 78.32 | 59.55 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
